Search Bar & Filters
Found 177 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the safety of LY3954068 in adults aged 50 to 85 with early symptomatic Alzheimers Disease. This Phase 1 study also investigates how much LY3954068 enters the bloodstream and examines its effects on Alzheimers disease markers. The study is divided into two parts to assess different dosing strategies. In Part A, each participant receives a single dose of LY3954068 or placebo injected into the spinal fluid. In Part B, participants may receive up to four doses of LY3954068 or placebo administered the same way. There is also an optional bridging period where participants might receive LY3954068 in a separate study. The study lasts about 45 weeks for Part A and up to 100 weeks for Part B, including screening. Participants will undergo various assessments such as spinal fluid sampling, blood tests, and PET scans using Flortaucipir F18 to observe tau protein changes. Safety is monitored by tracking adverse events related to the study drug. Cognitive tests like the Mini Mental State Examination and Clinical Dementia Rating are used to evaluate memory and dementia severity. Regular visits occur throughout the study to collect data, monitor health, and assess treatment effects.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Master Protocol study focusing on the safety and tolerability of multiple amyloid-targeting drugs in both healthy adults and individuals diagnosed with Alzheimers disease AD. This study aims to evaluate if these drugs can remove amyloid plaque, clumps of protein in the brain linked to AD. Participants will enroll in one of two substudies, either A1D-MC-AT01 or the upcoming A1D-MC-AT02, to assess these treatments. The study involves administering the drug LY4405094 or a placebo either intravenously IV or subcutaneously SC to healthy volunteers and AD participants. Participants with AD will also undergo amyloid positron emission tomography PET scans using Florbetapir F18 or Florbetaben F18 injected intravenously to help monitor amyloid plaque in the brain. The study uses a randomized, double-blind design and includes several substudies depending on participant health status. Participants will be closely monitored throughout the study period, which lasts up to 160 days from baseline. Evaluations include medical exams, electrocardiograms ECGs, cognitive assessments such as the Mini-Mental State Exam MMSE, and brain imaging with PET scans and magnetic resonance imaging MRI. Study partners will assist participants with Alzheimers disease by providing support and consent. Researchers will track the number of participants assigned to each substudy and assess safety and tolerability during the trial.
Actively Recruiting
Healthy Volunteer
This research aims to compare the pharmacokinetics of Navlimetostat after taking two different tablet formulationsa wet-granulation tablet and a dry-granulation tabletin healthy adult females who are not of childbearing potential. The study is a Phase 1, open-label, randomized, crossover trial designed to assess bioequivalence between the two formulations. Participants will receive specified doses of Navlimetostat on designated days in two separate treatment periods. Each participant will receive both tablet formulations in a randomized order, allowing comparison within the same individual. The study will assess drug concentration levels and other pharmacokinetic measures over the course of the treatment periods. During the study, participants will undergo physical examinations, vital sign monitoring, 12-lead ECGs, and laboratory tests including assessments of renal and hepatic function. Researchers will measure outcomes such as maximum plasma concentration, area under the concentration-time curve, and record any adverse events up to approximately day 37. The total participation duration includes dosing and follow-up assessments to monitor safety and drug behavior in the body.
Actively Recruiting
Researchers are evaluating DT120, a psychoactive drug acting mainly on serotonin 2A receptors, for treating adults aged 18 to 74 with major depressive disorder MDD. This Phase 3 trial compares DT120 to placebo over 12 weeks in a double-blind, randomized, and triple-blind design to assess its efficacy and safety. Participants must have a confirmed diagnosis of MDD with specific symptom severity and duration, without major psychiatric or unstable medical conditions. The study includes a 12-week double-blind period where participants receive a single dose of either DT120 at one of two dose levels or placebo. This is followed by a 40-week open-label extension phase where all participants may receive DT120 with monitoring for retreatment based on safety and symptoms. The trial evaluates multiple outcomes related to depression severity, symptom improvement, anxiety, sexual function, quality of life, and work productivity. Participants will undergo regular assessments including depression rating scales like MADRS and CGI, anxiety scales, and questionnaires on sexual functioning and daily activity impact. Monitoring continues throughout the extension phase to assess treatment durability and response. The total participation may last up to 52 weeks, with evaluations at several timepoints to understand treatment effects and safety over both study phases.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
1-10 of 177
1